Table 2

Placebo-Subtracted Changes From Baseline by Quartiles

Month 4Month 12Month 24End Point
V-PnV-PnV-PnV-Pn
LVIDd (cm)
 Q1−0.10*520−0.02466−0.05232−0.05528
 Q2−0.06527−0.03468−0.07229−0.09*537
 Q3−0.06636−0.08*556−0.00293−0.05649
 Q4−0.06559−0.11*467−0.11220−0.09574
EF (%)
 Q10.216590.875880.832830.20667
 Q20.785161.33*449−0.162250.58527
 Q31.00*5111.66*4561.042291.40*521
 Q41.07*5351.26*4541.192231.12*542

P = placebo; V = valsartan; V-P = placebo-subtracted changes from baseline, based on least-square mean values by analysis of co-variance; other abbreviations as in Table 1.

  • * The letter “n” represents the lower sample size for either valsartan or placebo. Values with an asterisk and in boldare for p < 0.05. Across-quartile changes are not significant.